Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Chris Schott
JPM

Chris Schott

J.P. Morgan
Wall Street Analyst
★★★★☆
#531
on 13Foresight · ranked by our own returns
72%
Success Rate
+5.8%
Average Return
62 of 86 calls profitable · -128.9% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 72% of Chris Schott's ratings turned a profit when each position was held for 2 year — averaging +5.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

83 Buy 35 Hold 2 Sell
Chris's Stock Coverage 27 ratings · 2026-11-14
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return vs S&P 500 ⓘ
REGN
Regeneron
 Oct 30, 2026 BUY Strong Buy
-12.1% avg upside
60 analysts
$1050.00
13.21% Upside
 +3.0% ·
MRK
Merck & Company
 Oct 30, 2026 BUY Strong Buy
-3.5% avg upside
44 analysts
$175.00
16.96% Upside
 -1.7% ·
GILD
Gilead Sciences
 Oct 30, 2026 BUY Strong Buy
-27.3% avg upside
66 analysts
$190.00
11.33% Upside
 -0.8% ·
LLY
Eli Lilly & Co
 Oct 30, 2026 BUY Strong Buy
-16.7% avg upside
50 analysts
$1650.00
16.33% Upside
 +0.7% ·
BIIB
Biogen
 Oct 28, 2026 BUY Strong Buy
+6.6% avg upside
53 analysts
$325.00
28.24% Upside
 +3.8% ·
AMRX
Amneal Pharmaceuticals
 Oct 22, 2026 BUY Strong Buy
-10.1% avg upside
19 analysts
$24.00
11.64% Upside
 +4.4% ·
VTRS
Viatris
 Oct 21, 2026 HOLD Buy
+25.5% avg upside
22 analysts
$20.00
5.04% Upside
 +13.0% ·
PRGO
Perrigo Company
 Oct 21, 2026 HOLD Buy
+333.3% avg upside
20 analysts
$15.00
4.97% Downside
 +6.5% ·
ELAN
Elanco Animal Health
 Oct 16, 2026 BUY Strong Buy
+35.1% avg upside
20 analysts
$33.00
43.18% Upside
 +13.5% ·
ZTS
Zoetis
 Oct 16, 2026 BUY Buy
+43.7% avg upside
25 analysts
$115.00
44.33% Upside
 +5.3% ·
IDXX
Idexx Laboratories
 Oct 16, 2026 BUY Buy
+30.3% avg upside
19 analysts
$750.00
36.05% Upside
 +23.6% ·
IL:TEVA
Teva
 Oct 11, 2026 BUY Strong Buy
+18.1% avg upside
8 analysts
$15722.83
22.78% Upside
 +7.5% ·
PFE
Pfizer
 Oct 09, 2026 HOLD Buy
+9.2% avg upside
46 analysts
$30.00
1.66% Downside
 +5.2% ·
ABBV
AbbVie
 Oct 08, 2026 BUY Strong Buy
-14.5% avg upside
47 analysts
$300.00
1.68% Upside
 +8.3% ·
BMY
Bristol-Myers Squibb
 Oct 08, 2026 BUY Buy
-2.2% avg upside
42 analysts
$73.00
16.91% Upside
 +4.5% ·
JNJ
Johnson & Johnson
 Sep 29, 2026 HOLD Strong Buy
-9.1% avg upside
40 analysts
$285.00
4.34% Upside
 +6.0% ·
RPRX
Royalty Pharma
 Aug 10, 2026 BUY Strong Buy
-12.2% avg upside
15 analysts
$62.00
7.76% Downside
 +19.3% ·
AMGN
Amgen
 Aug 06, 2026 HOLD Buy
-29.9% avg upside
57 analysts
$350.00
24.97% Downside
 +16.0% ·
OGN
Organon
 Feb 13, 2026 SELL Sell
+7.4% avg upside
9 analysts
$11.00
20.51% Downside
 -89.4% ·
CHRS
Coherus Biosciences
 May 25, 2023 HOLD Buy
+1336.6% avg upside
19 analysts
$8.00
863.74% Upside
 -82.3% ·
TSE:BHC
Bausch Health Companies
 Jul 28, 2022 HOLD Buy
+386.9% avg upside
30 analysts
 — +50.9% ·
TXMD
TherapeuticsMD
 May 19, 2020 HOLD Hold
+247.3% avg upside
8 analysts
 — · ·
DE:MRK
Merck KGaA
 Mar 09, 2020 BUY Buy
-7.2% avg upside
34 analysts
$87.46
42.25% Downside
 +75.0% ·
PCRX
Pacira Pharmaceuticals
 Feb 20, 2020 HOLD Hold
+11.8% avg upside
23 analysts
$54.00
48.48% Upside
 +27.8% ·
SNNAQ
Sienna Biopharmaceuticals
 May 13, 2019 HOLD Buy
+299999900.0% avg upside
2 analysts
 — · ·
KALA
KALA BIO
 Nov 17, 2017 BUY Strong Buy
+125847.8% avg upside
9 analysts
$35.00
21048.02% Upside
 · ·
AMRN
Amarin
 Oct 17, 2013 HOLD Buy
-28.6% avg upside
18 analysts
 — -1.0% ·
🔒 22 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Chris Schott — Frequently Asked Questions
How accurate are Chris Schott's stock ratings?
Based on the calls 13Foresight could measure, about 72% of Chris's ratings were profitable over a one-year hold, with an average return of +6.3% per rating, or -127.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Chris ranked on 13Foresight?
Chris Schott is currently ranked #531 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Chris cover?
Chris most recently has ratings on REGN, MRK, GILD, LLY, BIIB, AMRX, VTRS, PRGO, ELAN, ZTS, IDXX, IL:TEVA and 15 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.